Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)

PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 1, 2023

Study Completion Date

April 30, 2024

Conditions

Diabetes Mellitus, Type 2Cognitive Functions Confusion

Interventions

DRUG

Canagliflozin

12 weeks of Canagliflozin(100mg/day) treatment

DRUG

Sitagliptin

12 weeks of Sitagliptin (100mg/day) treatment

Trial Locations (1)

Zhiming Zhu, Chongqing

All Listed Sponsors

lead

Third Military Medical University

OTHER